A novel SHIP1-selective inhibitor to induce blood cell recovery and stem cell engraftment

Background:

Hematopoiesis, the process by which blood cells are formed, is critical for maintaining immune function and overall health. Patients undergoing myelosuppressive chemotherapy, radiation therapy, or stem cell transplantation often experience significant reductions in neutrophil and platelet counts, leaving them vulnerable to infections and bleeding complications. To address these risks, clinicians commonly administer hematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and thrombopoietin (TPO) to stimulate the production of neutrophils and platelets, respectively. However, the effectiveness and safety of current strategies to boost blood cell counts remain areas of active research, as rapid and robust hematologic recovery is crucial for patient outcomes. Current approaches to enhancing hematopoietic recovery primarily rely on exogenous administration of recombinant growth factors or cytokines. While these therapies can be effective, they often require repeated dosing, are expensive, and may induce immune reactions or other adverse effects. Additionally, the response to these agents can be variable, and some patients exhibit inadequate recovery or develop resistance over time. There is also a lack of specificity in targeting the underlying regulatory mechanisms that control endogenous production of growth factors, limiting the ability to fine-tune hematopoietic responses. These limitations underscore the need for more targeted, efficient, and safer methods to stimulate blood cell production, particularly in vulnerable patient populations.

Technology Overview:

A32 is a highly selective small molecule inhibitor that targets the active site of the SHIP1 enzyme, identified through advanced AI-based screening and validated by in vitro assays with recombinant SHIP1. This compound demonstrates remarkable specificity, significantly inhibiting SHIP1 activity while showing no measurable effect on the closely related SHIP2 enzyme. In vivo studies in mice reveal that A32 treatment leads to a dramatic increase in hematopoietic growth factors, including a 1000-fold rise in steady-state granulocyte colony-stimulating factor (G-CSF) and a twofold increase in thrombopoietin (TPO). These effects suggest that A32 can robustly stimulate the production of neutrophils and platelets, making it a promising candidate for enhancing hematologic recovery and immune function. What sets A32 apart is its exceptional selectivity and the innovative approach used in its discovery. Unlike other inhibitors that may affect multiple enzymes and cause off-target effects, A32’s specificity for SHIP1 minimizes unwanted interactions, reducing potential side effects. The use of AI-driven screening in collaboration with Atomwise enabled the rapid identification of this precise inhibitor, streamlining the drug discovery process. Furthermore, the pronounced in vivo effects on G-CSF and TPO production position A32 as a unique therapeutic tool for accelerating recovery from myelosuppressive treatments, improving stem cell engraftment, and bolstering innate immunity in vulnerable patient populations. This combination of targeted action, clinical relevance, and cutting-edge discovery methods distinguishes A32 from existing solutions in hematologic and immunologic support.

Advantages:

•    Highly selective inhibition of SHIP1 enzyme without affecting SHIP2
•    Significant increase in hematopoietic growth factors G-CSF and TPO
•    Enhances neutrophil and platelet production for improved blood cell recovery
•    Potential to accelerate recovery after myelosuppressive chemotherapy, radiation, or stem cell transplantation
•    May boost innate immunity against fungal infections in immunocompromised patients
•    Could improve blood clotting in patients with bleeding disorders

Applications:

•    Accelerating hematologic recovery post-chemotherapy
•    Enhancing stem cell transplantation engraftment
•    Treating neutropenia in immunocompromised patients
•    Improving platelet counts in bleeding disorders
•    Boosting innate immunity against infections

Intellectual Property Summary:

Patent pending

Stage of Development:

TRL 3

Licensing Status:

This technology is available for licensing.